COMPARATIVE EFFICIENCY OF NEOBUTINE® RETARD, FILM-COATED PROLONGED-RELEASE TABLETS 300 MG, AND TRIMEDAT®, TABLETS 200MG, IN PATIENTS WITH IRRITABLE BOWEL SYNDROME
- Authors: Borodulina E.V1, Mareyev I.V1, Kolokoltsova M.Y.1, Samykina I.A1, Udut V.V1
-
Affiliations:
- Scientific Research Institute of Pharmacology and Regenerative Medicine n.a. E.D. Goldberg of the FSBIS “Tomsk National Research Medical Center" of Russian Academy of Sciences
- Issue: No 5S (2017)
- Pages: 72-77
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/294361
- ID: 294361
Cite item
Abstract
In a randomized clinical trial involving 60 patients with irritable bowel syndrome (IBS), a comparison of the efficacy and safety of the use of Neobutine® Retard (film-coated prolonged- release tablets 300 mg, manufactured by AO FP «Obolenskoe»), and Trimedat® tablets 200 mg (manufactured by OAO «Valenta Pharmaceutics», Russia) was performed. The objectives of the study also included an assessment of the quality of life of patients and the compliance with treatment in comparison with the variants of treatment of IBS. Administration of Neobutine® Retard 300 mg and Trimedate® 200 mg lead to significant and comparable positive clinical effects for the relief of IBS symptoms. It is shown that therapy with trmebutine preparations (opioid receptor agonists) significantly improves the quality of life of patients and leads to a reduction in the time of achieving remission of IBS. The recommended regimen of treatment with Neobutine® Retard (300 mg twice a day) is superior to the traditional regimen of treatment with Trimedat® (200 mg 3 times a day).
Full Text
About the authors
E. V Borodulina
Scientific Research Institute of Pharmacology and Regenerative Medicine n.a. E.D. Goldberg of the FSBIS “Tomsk National Research Medical Center" of Russian Academy of Sciences
Email: elena.borodulina@pharmso.ru
Department of Therapeutic Drug Monitoring
I. V Mareyev
Scientific Research Institute of Pharmacology and Regenerative Medicine n.a. E.D. Goldberg of the FSBIS “Tomsk National Research Medical Center" of Russian Academy of Sciences
M. Yu Kolokoltsova
Scientific Research Institute of Pharmacology and Regenerative Medicine n.a. E.D. Goldberg of the FSBIS “Tomsk National Research Medical Center" of Russian Academy of Sciences
I. A Samykina
Scientific Research Institute of Pharmacology and Regenerative Medicine n.a. E.D. Goldberg of the FSBIS “Tomsk National Research Medical Center" of Russian Academy of Sciences
V. V Udut
Scientific Research Institute of Pharmacology and Regenerative Medicine n.a. E.D. Goldberg of the FSBIS “Tomsk National Research Medical Center" of Russian Academy of Sciences
References
- Белоусова Е.А. Идиопатический медленнотранзитный запор: механизмы развития и возможности лечения. Фарматека. 2010; 15:18-23.
- Holzer P. Opioid receptors in gastrointestinal tract. Regulatory peptides. 2009;155(1-3): 11-3.
- Ивашкин В.Т., Драпкина О.М. Современные возможности применения тримебутина в лечении хронической абдоминальной боли. РЖГГК. 2008;5:12-6.
- Тропская Н.С., Попова Т.С. Механизм действия тримебутина в коррекции функциональных расстройств желудочно-кишечного тракта. Кл. гастроэнтерология и гепатология. Русское издание. 2008;1(4):294-97.
- Брюшинина О.С., Гурто Р.В., Соловьев М.А., Бородулина Е.В., Трифонова О.Ю., Гриднева Т.Д., Удут В.В. Проблемные вопросы изучения фармакокинетики тримебутина. Бюллетень физиологии и патологии дыхания. 2014;54:82-6.
- Гланц С. Медико-биологическая статистика. Пер. с англ. М., 1998. С. 459.
- Минушкин О.Н., Елизаветина Г.А. Патофизиология абдоминальной боли. Современные подходы к терапии моторных нарушений. Эффективная фармакотерапия/ Гастроэнтерология. 2012;3:52-60.
- Трухан Д.И., Гришечкина И.А., Быховцев Н.А. Тримебутин в лечении синдрома раздраженного кишечника и других функциональных гастроинтестинальных расстройств. Медицинский совет/Гастроэнтерология. 2016;19:82-6.
- Lee H.T., Kim B.J. Trimebutine as a modulator of gastrointestinal motility. Arch. Pharmacol. Res. 2011;34:861-64.
- Dumitrascu D.L., Stănculete M. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome. Rom. J. Intern. Med. 2006;44(3): 273-80.